Menu Close
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Clinical
    • Critical Care
    • Procedures
    • COVID-19
  • Practice Management
    • Quality
    • Public Policy
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Learning Portal
    • The Hospital Leader Blog
    • From SHM
    • SIG Spotlight
    • Chapter Spotlight

An Official Publication of
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Clinical
    • Critical Care
    • Procedures
    • COVID-19
  • Practice Management
    • Quality
    • Public Policy
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Learning Portal
    • The Hospital Leader Blog
    • From SHM
    • SIG Spotlight
    • Chapter Spotlight

Heart Failure

  • Article

    Using POCUS of the Internal Jugular Vein to Predict Central Venous Pressure

    December 1, 2022

    Dr. Lawson Clinical question: Does point of care ultrasound (POCUS) of the internal jugular vein accurately predict central venous pressure? Background: Assessing volume status is critical to...

  • Article

    Tips for Properly Documenting and Coding HF

    December 1, 2022

    As hospitalists, we encounter heart failure (HF) regularly, but we have all seen it documented in a variety of ways (congestive HF (CHF), acute on chronic HF, heart failure with preserved ejection...

  • Article

    There is a Decreased Risk of Hospitalization from Heart Failure in Type II Diabetics Initiated on a SGLT2 Inhibitor When Compared to a GLP-1 Receptor Agonist

    September 1, 2022

    Dr. Huang Clinical question: Determine the cardiovascular risk outcome in type II diabetic patients initiated on an sodium-glucose cotransporter-2 (SGLT2)  inhibitor versus a glucagon-like...

  • Article

    How to Treat Heart Failure: New Updates

    August 1, 2022

    Case A 76-year-old man with a medical history of congestive heart failure (CHF) with left ventricular ejection fraction of 30%, hypertension, dyslipidemia, and recent hospitalization for CHF...

  • Article

    Effective therapy for heart failure with preserved ejection fraction

    January 7, 2022

      Dr. Anderson Clinical question: What effect do sodium-glucose cotransporter 2 (SGLT2) inhibitors have on outcomes in adults with heart failure with preserved ejection fraction...

  • 1
    News

    New data on rare myocarditis after COVID-19 vaccination

    December 8, 2021

    Most adolescents and young adults recover quickly from the rare complication of myocarditis following mRNA COVID-19 vaccination, a new study shows.

  • 1
    News

    SGLT2 inhibitor use tied to fewer atrial arrhythmias

    December 2, 2021

    A prospective study of nearly 14,000 patients who received an implantable cardiac device suggests that SGLT2-inhibitor treatment cuts atrial arrhythmias.

  • News

    Advanced CKD doesn’t derail empagliflozin in EMPEROR-preserved

    November 19, 2021

    Study shows empagliflozin led to a consistent, significant relative risk reduction compared with placebo in the primary endpoint.

  • 1
    News

    Empagliflozin a winner in challenging arena of stabilized acute HF

    November 19, 2021

    Early in-hospital initiation of SGLT2 inhibitors “should be considered the new standard of care” in most patients with heart failure regardless of their ejection fraction, says an expert observer.

  • 1
    News

    EMPEROR-Preserved findings confirmed in ‘true’ HFpEF patients

    November 17, 2021

    A landmark trial proved empagliflozin’s efficacy in HFpEF, but many patients had “moderately reduced” EFs. The findings hold up even without them.

1 2 3 … 19Next
  • About The Hospitalist
  • Contact Us
  • The Editors
  • Editorial Board
  • Authors
  • Publishing Opportunities
  • Subscribe
  • Advertise
  • Copyright © 2000-2023 by the Society of Hospital Medicine and related companies. All rights reserved. ISSN 1553-085X
  • Privacy Policy
  • Terms and Conditions
  • SHM’s DE&I Statement
  • Cookie Preferences